The White House will slash prices for obesity drugs for patients by hundreds of dollars after striking a landmark deal with Eli Lilly and Novo Nordisk.
At an event at the White House on Thursday, Donald Trump and administration officials said the list price for shots of Novo’s Ozempic and Wegovy would drop from at least $1,000 a month to $350 when bought through TrumpRx, the president’s new website that is scheduled to launch in early 2026.
Denmark-based Novo said the agreement would hurt its revenues and have a “negative, low single-digit impact on global sales growth in 2026”, the company said. However, the deal includes a three-year exemption from potential Trump tariffs, it added.
您已閱讀18%（691字），剩余82%（3188字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。